Wright will pay another $190 million if BioMimetic’s Augment Bone Graft technology receives FDA approval, and a decision is expected to be made between April 2013 and January 2014.
Wright Medical Group develops and manufactures orthopedic devices and will incorporate BioMimetic’s biologics offerings.
More Articles on Devices:
Invibio to Attend 2013 AAOS Annual Meeting
OsteoMed Launches QWIK Bone Fill Material
TranS1 Posts $12M 4Q Loss
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
